Overview

A Study to Assess the Electrophysiology, Safety, Tolerability, and Pharmacokinetics of SAGE-718 Using a Ketamine Challenge in Healthy Subjects

Status:
Completed

Trial end date:
2019-01-02

Target enrollment:

Participant gender:

Summary

This study is a phase 1, double-blind, placebo-controlled crossover study of single, oral dose of SAGE-718 using a ketamine challenge, to evaluate the electrophysiology, safety, tolerability, and pharmacokinetics in healthy subjects

Phase:

Phase 1

Details

Lead Sponsor:

Sage Therapeutics

Treatments:

Ketamine